0 Comments
Market Outlook
The global atorvastatin API market is predicted to enjoy 3.34% CAGR from 2018 to 2023 (forecast period) to touch a size of USD 425 million. High prevalence of cardiovascular diseases is expected to be the primary driver of the market during the forecast period. Rising cases of dyslipidemia in China can open up new avenues of growth for the market. High triglyceride levels and LDL cholesterol caused by obesity and sedentary lifestyles of patients can lend a helping hand to the atorvastatin API market. High volume of kidney disorders combined with high dosage of the drug in the elderly populace to control their cholesterol levels can bode well for the market. Approval of mass production of drugs from federal agencies can drive the atorvastatin API market growth. Recently, the U.S. FDA granted license to Morepen Laboratories for the production of atorvastatin calcium for export to the U.S. Strict regulation outlined by federal agencies as well as compliance for switching to green methods of production can bode well for the market. But adverse effects of the drug can hamper the market growth. also read @ http://www.marketwatch.com/story/atorvastatin-api-market-drivers-segmentations-key-players-analysis-forecast-by-2027-2021-05-06 Competitive Analysis Major industry participants in the global atorvastatin API market include Ind-Swift Labs Ltd, Teva Pharmaceutical Industries Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Anuh Pharma Ltd, Morepen Laboratories Ltd, Jubilant Life Sciences Ltd, Cadila Pharmaceuticals, Centrient Pharmaceuticals, Sun Pharmaceutical Industries Ltd, and Dr. Reddy’s Laboratories Ltd. Scaling of efforts to expedite research and development for mass production of the drug as well as compliance to latest standards are strategies employed by players to gain leverage over the competition. Segmentation Analysis The global atorvastatin API market is segmented by application. By application, it is segmented into dyslipidemia, hypertriglyceridemia, hypercholesterolemia, and others. The hypercholesterolemia segment is bound to generate close to USD 210.7 million by 2023. High prevalence of the disease can ensure the segment to display a strong CAGR of 4.09% during the forecast period. On the other hand, dyslipidemia segment is bound to have a high growth potential till 2023. Regional Analysis The Middle East & Africa, North America, Latin America, Asia Pacific (APAC), and Europe are regions taken into consideration in the compilation of the global atorvastatin API market report. North America accounted for 40.64% market share in 2017 due to the U.S. being one of the biggest contributors of the market. It can register 3.10% CAGR during the forecast period to gain high dividends for the global atorvastatin API market. The APAC region is expected to exhibit one of the strongest growth rates during the forecast period due to large approval of drugs in the region. Contract manufacturing and outsourcing companies which take up research and development of large pharmaceutical companies have widened the potential of the market. China, in particular, is touted to exhibit 5.86% CAGR during the forecast period. The Europe atorvastatin API market is touted to exceed a valuation of USD 131 million by 2023. Rising cases of dyslipidemia and hypercholesterolemia are primarily fueling the market demand. France and the U.K. are major contributors in the region. Expansions of production facilities to create generic versions of the Lipitor drug is likely to culminate in higher bottomline margins for players. Recently, DSP Sinochem Pharmaceuticals has launched Rosuvastatin for its clients as well as producing them in large quantities for third-party customers. Get access to full summary @ https://www.marketresearchfuture.com/reports/atorvastatin-api-market-7885 related reports Global Mammography Market - Forecast to 2027 Osteoporosis Drugs Market Report – Forecast 2027 Global Anesthesia Drugs Market - Global Forecast To 2027 About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Botulinum Toxin Market Highlights
Botulinum Toxin Market is expected to register a CAGR of 10.3% during the forecast period, with a market value of USD 9,442.93 Million by 2025. Botulinum toxin is known as one of the most poisonous biological substance. It is a neurotoxin produced by the bacterium Clostridium botulinum. There are seven distinct forms of botulinum toxin, types A–G. Four of these (types A, B, E, and rarely F) cause human botulism. Botulinum toxin A and B are used for therapeutic and aesthetic procedures. The increasing cases of spasticity, cervical dystonia and chronic migraine, surge in demand for facial aesthetic, and rising number of product launches and approvals by key players are likely to drive the growth of the global botulinum toxin market during the forecast period. Botulinum Toxin Market Segment Analysis The Global Botulinum Toxin Market, by type, has been segmented into botulinum toxin type A and B. Rising adoption of botulinum toxin in aesthetic procedures as compared to tissue fillers and increasing product approvals by regulatory authorities is anticipated to drive the growth of this segment during the forecast period. As per the Plastic Surgery Statistics Report published in 2018 by the American Society of Plastic Surgeons, the number of cosmetic minimally-invasive procedures involving the use of botulinum toxin type A was 7.43 million in 2018, whereas the processes involving the use of soft tissue fillers were 2.67 million in 2018 in the US.’ The Global Botulinum Toxin Market, by application segment, has been segmented into therapeutic application and aesthetics applications. The therapeutics segment has been further divided into a chronic migraine, spasticity, cervical dystonia, overactive bladder, blepharospasm, and others. Based on end-user, the global botulinum toxin market has been classified into dermatology centers, hospitals & clinics, and others. Botulinum Toxin Market Regional Analysis The Global Botulinum Toxin Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to hold the largest share of the global botulinum toxin market. The Americas is divided into North America and Latin America. North America has been further subdivided into the US and Canada. The increasing product approvals, rising cases of spasticity, and the presence of major manufacturers such as US WorldMeds, LLC., Evolus, Inc., Hugel, Inc., and Revance Therapeutics, Inc. in the region are expected to drive the market growth in this region. Europe established substantial growth in the market owing to rising botulinum toxin procedures and the presence of developed economies such as Germany, the UK, and France. Additionally, there is an increasing demand for minimally invasive cosmetic procedures to enhance the young-looking appearance, which in turn is driving the growth of the market in this region. Asia-Pacific is estimated to be the fastest-growing region in the global market due to the growing geriatric population, rising per capita disposable income, developing healthcare infrastructure, medical tourism, booming entertainment industry, and rising investments by major players in the regional market are likely to drive the growth of the market. The botulinum toxin market in the Middle East & Africa is expected to grow due to the rising awareness about botulinum toxin coupled with developing healthcare infrastructure and rising demand for products from countries like Saudi Arabia and UAE. Botulinum Toxin Market Key Players MRFR recognizes the following companies as the Key Players in the Global Botulinum Toxin Market— Allergan PLC, Merz Pharma GmbH & Co KGaA, Galderma S.A., Daewoong Pharmaceutical Co., Ltd, Ipsen Pharma, US WorldMeds, LLC. (Solstice Neurosciences, LLC), Evolus, Inc., Hugel, Inc, Medytox, Revance Therapeutics, Inc., and others. Browse Full Report details at: https://www.marketresearchfuture.com/reports/botulinum-toxin-market-8567 RELATED REPORTS Global Wound Closure Device Market Research Report- Forecast to 2027 Contraceptive Pills Market Research Report- Global Forecast To 2027 Dermatology Diagnostic device Market Research Report- Global Forecast To 2027 About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Global Rheumatoid arthritis market Information, by drug type (Nonsteroidal anti-inflammatory drug type (NSAID), Steroids, Biologic agents) by diagnosis (C-Reactive Protein (CRP) Test, CCP, ESR test) by treatment (Synovectomy, Tendon repair, Joint fusion) - Forecast to 2022
Market Research Future published a research report on Global rheumatoid arthritis diagnosis market growth Research Report- Forecast To 2022. Report gives a clear picture of current market scenario which includes past and estimated future market size. The report provides detail information and strategies of top key players in the industry. The report also gives a broad study about different markets segments and regions. Overview: According to the report published by Market Research Future (MRFR), the global rheumatoid arthritis market can expect robust growth during the forecast period (2016-2022). Rheumatoid arthritis is an autoimmune disorder that makes joints its primary targets. The joints get swollen, warm, and the disease makes it painful. The probability of joints from both sides getting affected is alarmingly high, like if the wrist gets affected on the left first, then a chance of the right becoming prone to the disease is relatively higher. Segmentation: MRFR’s report on the global rheumatoid arthritis market has been segmented by drug type, diagnosis, and treatment. Based on the drug type, the rheumatoid market can be segmented into steroids, non-steroidal anti-inflammatory drug type (NSAID), and disease-modifying anti-rheumatic drug type (DMARDs) and biologic agents. On the basis of treatment, the rheumatoid market includes synovectomy, tendon repair, joint fusion, and total joint replacement. Based on the diagnosis, the rheumatoid arthritis market includes C - reactive protein (CRP) test, CCP, ESR (Erythrocyte Sedimentation Rate) test, and synovial fluid analysis. Regional Segmentation : Rheumatoid Arthritis Market The regional segmentation of the global rheumatoid arthritis market segments the market into regional markets namely North America, Europe, Asia Pacific, and the Middle East & Africa. North America is the biggest market due to advanced medical facilities being available here, and it is expected to grow during the forecast period. The cream of this market comprises of the United States of America (USA) and Canada. Europe, the second largest market for rheumatoid arthritis is also expected to grow during the forecast period. After North America, Europe has maximum advanced medical facilities. Maximum revenue of this market comes from France, Germany, Italy, Spain, and the United Kingdom (UK), followed by the rest of Europe. Global Rheumatoid arthritis market Information, by drug type (Nonsteroidal anti-inflammatory drug type (NSAID), Steroids, Biologic agents) by diagnosis (C-Reactive Protein (CRP) Test, CCP, ESR test) by treatment (Synovectomy, Tendon repair, Joint fusion) - Forecast to 2022 @ https://www.marketresearchfuture.com/reports/rheumatoid-arthritis-market-1658 Competitive Landscape: These companies use strategies like merger, acquisition, marketing, branding, innovation, and other methods to stay abreast in the competitive market. Several companies like Pfizer Inc (U.S), AstraZeneca (U.K), Eli Lilly and company (U.S), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (U.S), Novartis AG (Switzerland), Vertex Pharmaceuticals Incorporated (U.S), Sanofi (France), and others are expected to make notable contributions. Browse Other Healthcare Related Reports Non-Invasive Monitoring Device Market Wearable Sensors Market About Market Research Future At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services Contact: https://www.marketresearchfuture.com/ |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
June 2021
Categories |